The African Union Purchases Millions of Moderna's mRNA COVID-19 Vaccines

Massachusetts-based Moderna, Inc. today announced a Memorandum of Understanding to make up to 110 million doses of the Company's COVID-19 vaccine (SpikeVax) available to the African Union.

The vaccine delivery schedule indicates the first 15 million doses in the fourth quarter of 2021, 35 million doses in the first quarter of 2022, and up to 60 million doses in the second quarter of 2022.

Moderna is also working on plans to fill doses of its COVID-19 vaccine in Africa as early as 2023, in parallel to building an mRNA vaccine manufacturing facility in Africa.

Furthermore, the Company recently announced an investment of up to $500 million to plan to build a state-of-the-art mRNA facility in Africa to produce up to 500 million doses of vaccines at the 50 µg dose level each year.

Stéphane Bancel, Moderna's CEO, stated in a press release, "We believe our vaccine can play an important role in addressing the needs of low-income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and superior storage and handling conditions."

"We recognize that access to COVID-19 vaccines continues to be a challenge in many parts of the world, and we remain committed to helping to protect as many people as possible around the globe."